Modulation of high affinity ATP-dependent cyclic nucleotide transporters by specific and non-specific cyclic nucleotide phosphodiesterase inhibitors
Permanent lenke
https://hdl.handle.net/10037/25698Dato
2014-11-07Type
Journal articleTidsskriftartikkel
Peer reviewed
Forfatter
Aronsen, Lena; Ørvoll, Elin Peggy Hanne Øien; Lyså, Roy Andre; Ravna, Aina Westrheim; Sager, GeorgSammendrag
Intracellular cyclic nucleotides are eliminated by phosphodiesterases (PDEs) and by ATP Binding cassette
transporters such as ABCC4 and ABCC5. PDE5 and ABCC5 have similar affinity for cGMP whereas ABCC5
has much higher affinity for cGMP compared with cAMP. Since the substrate (cGMP) is identical for these
two eliminatory processes it is conceivable that various PDE inhibitors also modulate ABCC5-transport.
Cyclic GMP is also transported by ABBC4 but the affinity is much lower with a Km 50–100 times higher
than for that of ABBCC5. The present study aimed to determine Ki-values for specific or relative specific
PDE5 inhibitors (vardenafil, tadalafil, zaprinast and dipyridamole) and the non-specific PDE inhibitors
(IBMX, caffeine and theophylline) for ABCC5 andABCC4 transport. The transport of [3
H]-cGMP (2 μM)
was concentration-dependently inhibited with the following Ki-values: vardenafil (0.62 μM), tadalafil
(14.1 μM), zaprinast (0.68 μM) and dipyridamole (1.2 μM), IBMX (10 μM), caffeine (48 μM) and theophylline (69 μM). The Ki-values for the inhibition of the [3
H]-cAMP (2 μM) transport were: vardenafil
(3.4 μM), tadalafil (194 μM), zaprinast (2.8 μM), dipyridamole (5.5 μM), IBMX (16 μM), caffeine (41 μM)
and theophylline (85 μM). The specificity for ABCC5 we defined as ratio between Ki-values for inhibition
of [3
H]-cGMP and [3
H]-cAMP transport. Tadalafil showed the highest specificity (Ki-ratio: 0.073) and
caffeine the lowest (Ki-ratio: 1.2).
Forlag
ElsevierSitering
Aronsen L, Ørvoll ephØ, Lyså RA, Ravna aw, Sager gs. Modulation of high affinity ATP-dependent cyclic nucleotide transporters by specific and non-specific cyclic nucleotide phosphodiesterase inhibitors. European Journal of Pharmacology. 2014;745:249-253Metadata
Vis full innførselSamlinger
Copyright 2014 The Author(s)